Synthesis, characterization, and cytotoxic activity of novel platinum(II) complexes derived from n-benzyl-ethylenediamine and oxalate: Research letter

Chemical Biology and Drug Design

Volumn 75, Issue 4, 2010, Pages 407-411

  Silva, Heveline ^a   Barra, Carolina V ^a   Rocha, Fillipe V ^a   De Almeida, Mauro V ^a   Cesar, Eloi T ^b   Da Silva Siqueira, Luciana M ^c   Lopes, Miriam T P ^c   Fontes, Ana P S ^a  

^a FEDERAL UNIVERSITY OF JUIZ DE FORA   (Brazil)

^b Colégio de Aplicação João XXIII ^*  (Brazil)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Anticancer agents; Cytotoxic activity; N benzyl ethylenediamine; Oxalate; Platinum(II) complexes

Indexed keywords

CARBOPLATIN; CISPLATIN; ETHYLENEDIAMINE DERIVATIVE; N BENZYL ETHYLENEDIAMINE; OXALIC ACID; PLATINUM DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; BREAST ADENOCARCINOMA; CARBON NUCLEAR MAGNETIC RESONANCE; CHEMICAL REACTION; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; KIDNEY CELL; LUNG NON SMALL CELL CANCER; MELANOMA CELL; METASTASIS; MOUSE; NONHUMAN; OVARY CELL; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SYNTHESIS;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHO CELLS; COORDINATION COMPLEXES; CRICETINAE; CRICETULUS; ETHYLENEDIAMINES; HUMANS; MICE; ORGANOPLATINUM COMPOUNDS; OXALATES;

CRICETINAE;

EID: 77449087466     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2009.00941.x     Document Type: Article

References (29)

1. Rosenberg B., Van Camp L., Trosco J.E., Mansour V.H. (1969) Platinum compounds: a new class of potent antitumor agents. Nature 222 : 385 386.
2. Pratt W.B., Ruddon R.W., Ensminger W.D., Maybaum J. (1994) The Anticancer Drugs. NY, USA : Oxford University Press 133 139 p.
3. Hambley T.W. (1997) The influence of structure on the activity and toxicity of Pt anti-cancer drugs. Coord Chem Rev 166 : 181 223.
4. Sykes A.G. (1988) Reactions of complexes of platinum metals with bio-molecules. Platinum Met Rev 32 : 170 178.
5. Pasini A., Zunino F. (1987) New cisplatin analogues - on the way to better antitumor agents. Angew Chem Int Ed Engl 26 : 615 624.
6. Farrell N., Qu Y., Hacker M.P. (1990) Cytotoxicity and antitumor activity of bis(platinum) complexes. A novel class of platinum complexes active in cell lines resistant to both cisplatin and 1,2-diaminocyclohexane complexes. J Med Chem 33 : 2179 2184.
7. Cvitkovic E., Spaulding J., Bethune V., Martin J., Whitmore W.F. (1977) Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. Cancer 39 : 1357 1361.
8. de Lena M., Lorusso V., Paradiso A., Tommasi S. (1987) Therapeutic efficacy of various dosages and modalities of administration. Inorganica Chim Acta 137 : 91 97.
9. Mathé G., Kidani Y., Sekiguichi M., Eriguchi M., Fredj G., Peytavin G., Misset J.L., Brienza S., de Vassals F., Chenu E., Bourut C. (1989) Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed Pharmacother 43 : 237 250.
10. Anjo A., Dantchew D., Mathé G. (1989) Notes on the cardiotoxicity of platinum complexes (except 1-OHP) in ultrastructural study. Biomed Pharmacother 43 : 265 266.
11. Bolelikas T., Vougiouka M. (2003) Cisplatin and platinum drugs at the molecular level. Oncol Rep 10 : 1663 1682.
12. Hirose T., Horichi N., Ohmori T., Shirai T., Sohma S., Yamaoka T., Ohnishi T., Adachi M. (2003) Phase I study of the combination of gemcitabien and nedaplatin for treatment of previously untreated advanced non-small cell lung cancer. Lung Cancer 39 : 91 97.
13. Gietema J.A., Veldhius G.J., Guchelaar H.J., Willemse P.H.B., Uges D.R.A., Cats A., Boonstra H., Van der Graof W.T.A., Sleijfer D.T., Devuies E.G.E., Mulder N.H. (1995) Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer. Br J Cancer 71 : 1302 1307.
14. Fiebig H.H., Heuss H., Vonpawel L., Gatzemeier U., Manegold C., Edler L., Berdel W. (1996) Phase II clinical trial of lobaplatin (D-19466) in pretreated patients with small-cell lung cancer. Onkologie 19 : 328 332.
15. Zou J., Dou P.Y., Wang K. (1997) Synthesis, antitumor activity and acute toxicity of diamine/diaminocyclohexane platinum(II) complexes with oxygen-ligating leaving group. J Inorg Biochem 65 : 145 149.
16. Beaumont K.P., Mcauliffe C.A., Cleare M.J. (1976) Platinum complexes of substituted ethylenediamines and their anti-tumor activity. Chem Biol Interact 14 : 179 193.
17. Paul A.K., Srivastava T.S., Chavan T.S., Chitnis M.P., Desai S., Rao K.K. (1996) Synthesis, characterization, cytotoxic, and DNA binding studies of some platinum(II) complexes of 1,2-diamine and α-diimine with 2-pyridinecarboxylate anion. J Inorg Biochem 61 : 179 196. (Pubitemid 26067623)
18. Farrell N. (1989) Transition Metal Complexes as Drugs and Chemotherapeutic Agents. Dordrecht, The Netherlands : Kluwer Academic Publishers 18 p.
19. de Almeida M.V., Cesar E.T., Felício E.C.A., Fontes A.P.S. (2000) Synthesis of platinum complexes from N-benzyl ethylenediamine derivatives. J Braz Chem Soc 11 : 154 158.
20. de Almeida M.V., Cesar E.T., Felício E.C.A., Fontes A.P.S., Berg R.N., Filho J.D.S. (2002) Synthesis of platinum complexes from N-benzyl-1,3-propanediamine derivatives, potencial antineoplasic agents. Molecules 7 : 405 411.
21. Cesar E.T., de Almeida M.V., Fontes A.P.S., Pereira-Maia E.C., Garnier-Suillerot A., Couri M.R.C., Felício E.C.A. (2003) Synthesis, characterization, cytotoxic activity, and cellular accumulation of dinuclear platinum complexes derived from N,N′-di-(2-aminoethyl)-1,3-diamino-2- propanol, aryl substituted N-benzyl-1,4-butanediamine, and N-benzyl-1,6- hexanediamines. J Inorg Biochem 95 : 297 305.
22. de Almeida M.V., Chaves J.D.S., Fontes A.P.S., Cesar E.T., Gielen M. (2006) Synthesis and characterization of platinum(II) complexes from trifluoromethyl phenylenediamine, picoline and N-benzyl ethylenediamine derivatives. J Braz Chem Soc 17 : 1266 1273.
23. II(1,2-trans-R,R-diaminocyclohexane)(X-Y) complexes. J Biol Inorg Chem 12 : 461 475.
24. 195Pt NMR spectroscopy: a chemometric approach. Coord Chem Rev 250 : 2158 2174.
25. von Angerer E., Egginger G., Kranzfelder G., Bernhauer H., Schonenberger H. (1982) N,N′-Dialkyl-1,2-bis(hydroxyphenyl)ethylenediamines and N,N′-dialkyl-4,5-bis(4-hydroxyphenyl)imidazolidines. Syntheses and evaluation of their mammary tumor inhibiting activity. J Med Chem 25 : 832 837.
26. Wappes B., Jennerwein M., von Angerer E., Schonenberger H., Engel J., Berger M., Wrobel K.H. (1984) Dichloro[1,2-bis(4-hydroxyphenyl)ethylenediamine] platinum(II) complexes: an approach to develop compounds with a specific effect on the hormone-dependent mammary carcinoma. J Med Chem 27 : 1280 1286.
27. Karl J., Gust R., Spruss T., Schneider M.R., Schonenberger H., Engel J., Wrobel K.H., Lux F., Haeberlin S.T. (1988) Ring-substituted [1,2-bis(4- hydroxyphenyl)ethylenediamine]dichloroplatinum(II) complexes: compounds with a selective effect on the hormone-dependent mammary carcinoma. J Med Chem 31 : 72 83.
28. Gust R., Beck W., Jaouen G., Schonenberger H. (2009) Optimization of cisplatin for the treatment of hormone dependent tumoral diseases: part 1: use of steroidal ligands. Coord Chem Rev 253 : 2742 2759.
29. Gust R., Beck W., Jaouen G., Schonenberger H. (2009) Optimization of cisplatin for the treatment of hormone-dependent tumoral diseases: part 2: use of non-steroidal ligands. Coord Chem Rev 253 : 2760 2779.